Market Challenges And Opportunities

Anaplastic Astrocytoma Treatment Market: Driver

Increasing number of drug candidate in pipeline, which may receive approval over the forecast period is expected to drive growth of the global anaplastic astrocytoma treatment market. Currently, there is only a drug, temozolomide (Temodar), approved by U.S. FDA for Anaplastic Astrocytoma. Temodar is an alkylating agent that has been approved for both conditions, newly diagnosed patients as well as refractory anaplastic astrocytoma patients, who have witnessed disease progression in spite of taking drug containing nitrosourea and procarbazine. However, there are multiple products in pipeline for the treatment of anaplastic astrocytoma. For instance, DCC-2618, a drug candidate developed by Deciphera Pharmaceuticals, Inc. is currently in Phase 1 clinical trials. The drug has also been granted orphan drug designation for the treatment of anaplastic astrocytoma and glioblastoma multiforme (GBM) in September 2017. Moreover, an experimental drug PAC-1 was cleared for the clinical trial of patients with anaplastic astrocytoma in November 2017. The drug candidate is being developed by Vanquish Oncology, Inc. The trial will determine if the drug candidate is safe to use in combination with a standard chemotherapy drug, temozolomide.

Anaplastic Astrocytoma Treatment Market: Restraint

Currently, there are three main forms of treatment for anaplastic astrocytoma – surgery, radiation, and chemotherapy. Out of these three, surgery is the first line of treatment in most of the cases. Only if, whole tumor cannot be safely excised or removed, patients are advised to go for other method of treatment. This treatment pattern i.e. drugs as second or third line of treatment has hampered the sales of pharmaceutical drugs such as Temodar, which in turn has restrained growth of anaplastic astrocytoma treatment market.